Clinical Trials · NCT04696042
Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Asan Medical Center
- Enrollment
- 71
- Start date
- Jan 2021
- Locations
- 1 site, South Korea
- Primary endpoint
- Progression-free survival rate at 2 years